Products are for research use only. Not for human use. We do not sell to patients. Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo

ChemLeader Biomedical Co.,Limited was founded in 2010, is a professional research chemical supplier specializing in R&D, manufacturing and sales. The headquarters is located in Shanghai International Medical Zone(SIMZ), Pudong New District, Shanghai, China, with over 30000 square feet sales office/ research laboratory and 20000 square feet pilot plant. Our branches in Xuzhou, Shandong, and Hong Kong.

We are committed to provide the highest quality products and the best service to pharmaceutical company and scientific research institutions in China and international markets. Our team has had extensive expertise and an excellent background in synthetic chemistry, project management, CRO, QC/QA, pilot plant etc.

As an innovation-driven and customer-focused company, we also specialize in custom synthesis of organic compounds, various drug intermediates as well as a variety of specialty and fine chemicals ranging from milligram to tons scale.

With our whole Professional team's efforts for many years we gain the admiration and trust from the domestic and overseas clients, and favorable position and Reputation in China Pharmaceutical and Fine Chemicals field. We are devoted to decreasing the production cost, optimizing the artwork, creating and keeping the accomplishment of best environmental, health, and safety performance in the industry.